60 acast.com Cancer Research Matters http://www.cancerreseachmatters.org.uk en Cancer Research UK Cancer, research,oncology,Cancer research UK,biology,clinical trials,tumour,science,cell biology,genetics,medical research Cancer Research UK A podcast for researchers from Cancer Research UK A podcast from Cancer Research UK that features some of the incredible researchers behind cancer research. We'll provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.


Entrepreneurial deep dive

The latest series is a special mini-series taking a deep dive into all things science entrepreneurship. 

Getting findings from discovery research in the lab to a tangible intervention is, really, the main game in town – but the leap from the lab to the generation of an actual product can be daunting. This series aims to de-mystify the various routes you can take to translate your work… from the earliest steps to forming a start-up company or licencing your work. 


You’ll meet technology-transfer experts, investors, patent attorneys, researchers – senior and early career – on their own translation journey and many more. Whether you want advice, other people’s translation tales or even a spot of inspiration… this series has something for you. 


20 years of...

The first series focusses on the 20th anniversary of Cancer Research UK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.

Hosted on Acast. See acast.com/privacy for more information.

]]> A podcast from Cancer Research UK that features some of the incredible researchers behind cancer research. We'll provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.


Entrepreneurial deep dive

The latest series is a special mini-series taking a deep dive into all things science entrepreneurship. 

Getting findings from discovery research in the lab to a tangible intervention is, really, the main game in town – but the leap from the lab to the generation of an actual product can be daunting. This series aims to de-mystify the various routes you can take to translate your work… from the earliest steps to forming a start-up company or licencing your work. 


You’ll meet technology-transfer experts, investors, patent attorneys, researchers – senior and early career – on their own translation journey and many more. Whether you want advice, other people’s translation tales or even a spot of inspiration… this series has something for you. 


20 years of...

The first series focusses on the 20th anniversary of Cancer Research UK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.

Hosted on Acast. See acast.com/privacy for more information.

]]> false Phil Prime phil.prime@cancer.org.uk 61fbe28ea451000014525587 cancer-research-matters episodic https://assets.pippa.io/shows/61fbe28ea451000014525587/1731075635971-5d7e7d2b-b647-42dc-ab2b-06a70d07cfcd.jpeg http://www.cancerreseachmatters.org.uk Cancer Research Matters Start-up – forging your own path... Start-up – forging your own path... Mon, 16 Dec 2024 16:14:35 GMT 33:56 676051ec27740406d81b3ba8 false https://shows.acast.com/cancer-research-matters/episodes/start-up-forging-your-own-path 676051ec27740406d81b3ba8 61fbe28ea451000014525587 start-up-forging-your-own-path full 2 3 There are trials and tribulations ahead, but honestly, could there be anything more exciting than grabbing the reigns of your own translation and driving it forward? In this episode we get to grips with the specifics of forming a start-up company, we speak to some successful academic founders, figure out what you need to think about as you pull the trigger and form your own company and get some behind-the-scenes gems from a biotech investor.  

Appearing in this episode:

Simon Boulton

Principal Group Leader, The Francis Crick Institute

Co-founder & VP Science Strategy, Artios Pharma Ltd

Chief Translation Advisor, Cancer Research UK

Simon’s lab has discovered new DNA repair genes and provided novel insights into cancer. In 2016, Simon helped to establish Artios Pharma Ltd - he is Vice President of Science Strategy alongside his academic roles at the Francis Crick Institute and Cancer Research UK.


Phil Masterson

Associate Director, Ventures, Cancer Research Horizons

Phil leads a team focussed on the creation of innovative and transformative oncology ventures, from ideation to launch. 


Professor Steven Pollard

Founder & CSO, Trogenix

Professor of Stem Cell and Cancer Biology, University of Edinburgh

Trogenix is uniting cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to create a revolutionary therapeutic approach. Steve's laboratory studies the molecular and cellular mechanisms that regulate stem cell identity and differentiation and how these operate in the context of human cancer.


Professor Sophia Karagiannis

Co-founder, Epsilogen

Professor of Translational Cancer Immunology and Immunotherapy, Kings Collage London

Sophia heads up a cancer antibody discovery team focused on immune cells and cancer and on the design of novel agents for solid tumours. She is also a founder of Epsilogen Ltd the first immuno-oncology company dedicated to developing IgE therapeutic agents for cancer.


Jonathan Tobin

Partner, Brandon Capital

Investor-in-residence, Cancer Research Horizons

Jonathan is a Partner with Brandon Capital where he heads the London office, and serves on the boards of Brandon portfolio companies Astronautx, Pheon Therapeutics, Myricx Bio, NRG Therapeutics, and Catalym. 

Professor Ed Tate

GSK Chair in Chemical Biology, Imperial College London

Satellite Group Leader, Francis Crick Institute

Co-founder, Myricxbio

Ed's research focusses on chemical biology and chemical proteomics. Myricxbio which is focused on discovering and developing novel payloads for antibody drug conjugates, based on inhibitors of the enzymes, N-myristoyltransferases (NMT) for the treatment of cancer.


Useful links:

Cancer Research Horizons Seed fund


Hosted on Acast. See acast.com/privacy for more information.

]]> There are trials and tribulations ahead, but honestly, could there be anything more exciting than grabbing the reigns of your own translation and driving it forward? In this episode we get to grips with the specifics of forming a start-up company, we speak to some successful academic founders, figure out what you need to think about as you pull the trigger and form your own company and get some behind-the-scenes gems from a biotech investor.  

Appearing in this episode:

Simon Boulton

Principal Group Leader, The Francis Crick Institute

Co-founder & VP Science Strategy, Artios Pharma Ltd

Chief Translation Advisor, Cancer Research UK

Simon’s lab has discovered new DNA repair genes and provided novel insights into cancer. In 2016, Simon helped to establish Artios Pharma Ltd - he is Vice President of Science Strategy alongside his academic roles at the Francis Crick Institute and Cancer Research UK.


Phil Masterson

Associate Director, Ventures, Cancer Research Horizons

Phil leads a team focussed on the creation of innovative and transformative oncology ventures, from ideation to launch. 


Professor Steven Pollard

Founder & CSO, Trogenix

Professor of Stem Cell and Cancer Biology, University of Edinburgh

Trogenix is uniting cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to create a revolutionary therapeutic approach. Steve's laboratory studies the molecular and cellular mechanisms that regulate stem cell identity and differentiation and how these operate in the context of human cancer.


Professor Sophia Karagiannis

Co-founder, Epsilogen

Professor of Translational Cancer Immunology and Immunotherapy, Kings Collage London

Sophia heads up a cancer antibody discovery team focused on immune cells and cancer and on the design of novel agents for solid tumours. She is also a founder of Epsilogen Ltd the first immuno-oncology company dedicated to developing IgE therapeutic agents for cancer.


Jonathan Tobin

Partner, Brandon Capital

Investor-in-residence, Cancer Research Horizons

Jonathan is a Partner with Brandon Capital where he heads the London office, and serves on the boards of Brandon portfolio companies Astronautx, Pheon Therapeutics, Myricx Bio, NRG Therapeutics, and Catalym. 

Professor Ed Tate

GSK Chair in Chemical Biology, Imperial College London

Satellite Group Leader, Francis Crick Institute

Co-founder, Myricxbio

Ed's research focusses on chemical biology and chemical proteomics. Myricxbio which is focused on discovering and developing novel payloads for antibody drug conjugates, based on inhibitors of the enzymes, N-myristoyltransferases (NMT) for the treatment of cancer.


Useful links:

Cancer Research Horizons Seed fund


Hosted on Acast. See acast.com/privacy for more information.

]]> Sharpen up – magnificent skills and where to find them... Sharpen up – magnificent skills and where to find them... Tue, 26 Nov 2024 11:46:15 GMT 35:10 6745b50718aa9bd6714a911e false https://shows.acast.com/cancer-research-matters/episodes/sharpen-up-magnificent-skills-and-where-to-find-them 6745b50718aa9bd6714a911e 61fbe28ea451000014525587 sharpen-up-magnificent-skills-and-where-to-find-them full 2 2 The special mini-series of Cancer Research Matters takes a deep dive into all things science entrepreneurship.


Right, so initial contact has been made… time to take those first steps in an entrepreneurial adventure. However, it’s clear that the many skills you have gathered as an academic – and they are considerable – you’ll need a few more to help you be successful in translating your research. So, what are they? What’s the best way to sharpen up? And how – exactly – can they help? Its all in this episode… plus: Do you know your design rights from your copyright? Me either... luckily we have a patent attorney to give us a vital primer on intellectual property protection.

   

Appearing in this episode:


Alessia Erico

Associate Director, Search and Evaluation, and Entrepreneurial Programmes Lead at Cancer Research Horizons


Alessia leads a team responsible for sourcing new opportunities arising from Cancer Research UK-funded science, in the UK and internationally, that have the potential of translating to the clinic.


Faith Howard

Postdoctoral Research Associate, University of Sheffield

Co-Founder at NANOncolytics


Faith is cofounder of NANOncolytics, a company developing nanoparticle technology to provide a less invasive strategy for treating inaccessible and aggressive tumours.


Matt de Vries

PhD student at the Institute of Cancer Research and Imperial College London,

co-founder of Sentinal 4D


Matt's work focuses on biomedical applications of 3D computer vision. In 2022, Matt was shortlisted for the Cancer Research Horizons Early Career Entrepreneur of the Year award for his work on co-founding Sentinal 4D.


Camille Terfve

Partner, Patent Attorney at Mewburn Ellis

Camille has expertise in bioinformatics/computational biology, digital health, AI in the life sciences, and advanced bioprocessing. 


Useful links:

Entrepreneurship training from Cancer Research Horizons

Venture Builder Incubator

Cancer Tech Accelerator

Hosted on Acast. See acast.com/privacy for more information.

]]> The special mini-series of Cancer Research Matters takes a deep dive into all things science entrepreneurship.


Right, so initial contact has been made… time to take those first steps in an entrepreneurial adventure. However, it’s clear that the many skills you have gathered as an academic – and they are considerable – you’ll need a few more to help you be successful in translating your research. So, what are they? What’s the best way to sharpen up? And how – exactly – can they help? Its all in this episode… plus: Do you know your design rights from your copyright? Me either... luckily we have a patent attorney to give us a vital primer on intellectual property protection.

   

Appearing in this episode:


Alessia Erico

Associate Director, Search and Evaluation, and Entrepreneurial Programmes Lead at Cancer Research Horizons


Alessia leads a team responsible for sourcing new opportunities arising from Cancer Research UK-funded science, in the UK and internationally, that have the potential of translating to the clinic.


Faith Howard

Postdoctoral Research Associate, University of Sheffield

Co-Founder at NANOncolytics


Faith is cofounder of NANOncolytics, a company developing nanoparticle technology to provide a less invasive strategy for treating inaccessible and aggressive tumours.


Matt de Vries

PhD student at the Institute of Cancer Research and Imperial College London,

co-founder of Sentinal 4D


Matt's work focuses on biomedical applications of 3D computer vision. In 2022, Matt was shortlisted for the Cancer Research Horizons Early Career Entrepreneur of the Year award for his work on co-founding Sentinal 4D.


Camille Terfve

Partner, Patent Attorney at Mewburn Ellis

Camille has expertise in bioinformatics/computational biology, digital health, AI in the life sciences, and advanced bioprocessing. 


Useful links:

Entrepreneurship training from Cancer Research Horizons

Venture Builder Incubator

Cancer Tech Accelerator

Hosted on Acast. See acast.com/privacy for more information.

]]> First contact – how big things come from small steps… First contact – how big things come from small steps… Sun, 10 Nov 2024 16:06:31 GMT 35:19 672de985a42e23dc4b9d9e13 false https://shows.acast.com/cancer-research-matters/episodes/first-contact-how-big-things-come-from-small-steps 672de985a42e23dc4b9d9e13 61fbe28ea451000014525587 first-contact-how-big-things-come-from-small-steps full 2 1 The special mini-series of Cancer Research Matters takes a deep dive into all things science entrepreneurship.


This first episode asks: why should entrepreneurship and translation interest researchers from an academic background? Isn’t this a tricky thing to navigate? What support is available? What kinds of research can be translated and what should researchers do if they think their work could lead to an intervention. It’s all in here – so get stuck in.


Appearing in this episode:


Simon Boulton

Principal Group Leader, The Francis Crick Institute

Co-founder & VP Science Strategy, Artios Pharma Ltd

Chief Translation Advisor, Cancer Research UK

Simon’s lab has discovered new DNA repair genes and provided novel insights into cancer. In 2016, Simon helped to establish Artios Pharma Ltd where he functions as Vice President of Science Strategy alongside his academic roles at the Francis Crick Institute and Cancer Research UK. Artios are developing new treatments that target DNA repair pathway vulnerabilities to selectively kill cancer cells. Simon is also Chief Translation Advisor at Cancer Research UK, with the remit to guide translation and commercialisation of novel cancer therapeutics.


Tony Hickson

Chief business officer, Cancer Research UK and Cancer Research Horizons

Tony leads the Commercial Partnerships team responsible for the commercialisation of IP from Cancer Research UK-funded projects, new start-up creation, licences and corporate alliances.


Faith Howard

Postdoctoral Research Associate, University of Sheffield

Co-Founder at NANOncolytics

Faith’s research interests are focused on delivery of therapeutics to disseminated tumours. This includes nanoenabled formulations and the development of appropriate models for studying immunotherapies. She is cofounder of NANOncolytics, a company developing nanoparticle technology to provide a less invasive strategy for treating inaccessible and aggressive tumours.


Tommy Rennison

Regional Translation Lead, Cancer Research Horizons

Tommy is responsible for sourcing and evaluating potential new projects for Cancer Research Horizons.


Phil Berry

Translation Executive at Cancer Research Horizons 

Phil is responsible for sourcing and evaluating potential new projects for Cancer Research Horizons.


Useful links

Cancer Research Horizons

Cancer Research Horizons entrepreneurial training

The Venture Builder Incubator

ICURe Programme

Hosted on Acast. See acast.com/privacy for more information.

]]> The special mini-series of Cancer Research Matters takes a deep dive into all things science entrepreneurship.


This first episode asks: why should entrepreneurship and translation interest researchers from an academic background? Isn’t this a tricky thing to navigate? What support is available? What kinds of research can be translated and what should researchers do if they think their work could lead to an intervention. It’s all in here – so get stuck in.


Appearing in this episode:


Simon Boulton

Principal Group Leader, The Francis Crick Institute

Co-founder & VP Science Strategy, Artios Pharma Ltd

Chief Translation Advisor, Cancer Research UK

Simon’s lab has discovered new DNA repair genes and provided novel insights into cancer. In 2016, Simon helped to establish Artios Pharma Ltd where he functions as Vice President of Science Strategy alongside his academic roles at the Francis Crick Institute and Cancer Research UK. Artios are developing new treatments that target DNA repair pathway vulnerabilities to selectively kill cancer cells. Simon is also Chief Translation Advisor at Cancer Research UK, with the remit to guide translation and commercialisation of novel cancer therapeutics.


Tony Hickson

Chief business officer, Cancer Research UK and Cancer Research Horizons

Tony leads the Commercial Partnerships team responsible for the commercialisation of IP from Cancer Research UK-funded projects, new start-up creation, licences and corporate alliances.


Faith Howard

Postdoctoral Research Associate, University of Sheffield

Co-Founder at NANOncolytics

Faith’s research interests are focused on delivery of therapeutics to disseminated tumours. This includes nanoenabled formulations and the development of appropriate models for studying immunotherapies. She is cofounder of NANOncolytics, a company developing nanoparticle technology to provide a less invasive strategy for treating inaccessible and aggressive tumours.


Tommy Rennison

Regional Translation Lead, Cancer Research Horizons

Tommy is responsible for sourcing and evaluating potential new projects for Cancer Research Horizons.


Phil Berry

Translation Executive at Cancer Research Horizons 

Phil is responsible for sourcing and evaluating potential new projects for Cancer Research Horizons.


Useful links

Cancer Research Horizons

Cancer Research Horizons entrepreneurial training

The Venture Builder Incubator

ICURe Programme

Hosted on Acast. See acast.com/privacy for more information.

]]> Careers and the cutting edge – four themes from a year of cancer research leaders Careers and the cutting edge – four themes from a year of cancer research leaders Mon, 13 Feb 2023 16:10:19 GMT 28:42 63ea60eb4d5d33001134b177 false https://shows.acast.com/cancer-research-matters/episodes/careers-and-the-cutting-edge-four-themes-from-a-year-of-canc 63ea60eb4d5d33001134b177 61fbe28ea451000014525587 careers-and-the-cutting-edge-four-themes-from-a-year-of-canc full 1 9 This episode features a round-up of the best of the first series of Cancer Research Matters.

It features some of the fantastic researchers that we have interviewed over the past year – including Professor Steve Jackson, Professor Ruth Plummer, Dr Simon Boulton, Professor Sir Leszek Borysiewicz, Professor Karen Vousden, Professor Richard Gilbertson and Professor Charles Swanton.

In this episode I tease out four themes that emerged over this first series that give some interesting insights into how we work as scientists, research leaders and research translators. 

Hosted on Acast. See acast.com/privacy for more information.

]]> This episode features a round-up of the best of the first series of Cancer Research Matters.

It features some of the fantastic researchers that we have interviewed over the past year – including Professor Steve Jackson, Professor Ruth Plummer, Dr Simon Boulton, Professor Sir Leszek Borysiewicz, Professor Karen Vousden, Professor Richard Gilbertson and Professor Charles Swanton.

In this episode I tease out four themes that emerged over this first series that give some interesting insights into how we work as scientists, research leaders and research translators. 

Hosted on Acast. See acast.com/privacy for more information.

]]> Break beat – 20 years of understanding genomic instability Break beat – 20 years of understanding genomic instability Fri, 20 Jan 2023 12:26:23 GMT 28:37 63ca71a61e5f8a0011f7964a false https://shows.acast.com/cancer-research-matters/episodes/break-beat-20-years-of-understanding-genomic-instability 63ca71a61e5f8a0011f7964a 61fbe28ea451000014525587 break-beat-20-years-of-understanding-genomic-instability full 1 8 Cancer Research Matters, a new Podcast from Cancer Research UK featuring some of the incredible researchers behind cancer research. The idea is to drive and provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

The first series focusses on the 20th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.


This episode features Dr Simon Boulton. Simon is a leader in the field of DNA damage sensing, repair and telomere maintenance. He is Principal Group Leader and Assistant Research Director of translation at the Francis Crick Institute, and Director of RadNet, City of London – a CRUK initiative focused on improving radiation treatment for cancer patients. Simon is also co-founder and Vice President of Science Strategy of the spin-out Artios Pharma and Chair of CRUK’s Discovery Research Committee.

He talks about the dawn of the field of DNA damage repair, why an entrepreneurial approach to your research is so valuable and the importance of venture capital in the innovation landscape. 


Useful links

Explore the formation of Artios Pharma and the role of Cancer Research Horizons in translation

https://news.cancerresearchuk.org/2021/11/05/taking-on-dna-repair-to-tackle-cancer/


Explore RadNet. Whether you’re a cancer biologist, health professional, engineer or physical scientist, RadNet is an exciting and rewarding opportunity to apply your expertise and knowledge

https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/radnet-our-radiation-research-network


Register your interest for the CRUK-ARR Radiation Research Conference https://forms.office.com/Pages/ResponsePage.aspx?id=L4lzROBx_EaN7Cc5ArUTSeNZ7IzS7O9ItRV1smdjkd1UMDBYRUI1SzRPSThYNTZEUDhSSzZSSUJKVi4u


Find out how Cancer Research Horizons can help you translate your work

https://www.cancerresearchhorizons.com/collaborate-us/researchers


Listen to Professor Steve Jackson on a previous episode

https://shows.acast.com/cancer-research-matters/episodes/translation-tales-20-years-of-forming-spinout

Hosted on Acast. See acast.com/privacy for more information.

]]> Cancer Research Matters, a new Podcast from Cancer Research UK featuring some of the incredible researchers behind cancer research. The idea is to drive and provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

The first series focusses on the 20th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.


This episode features Dr Simon Boulton. Simon is a leader in the field of DNA damage sensing, repair and telomere maintenance. He is Principal Group Leader and Assistant Research Director of translation at the Francis Crick Institute, and Director of RadNet, City of London – a CRUK initiative focused on improving radiation treatment for cancer patients. Simon is also co-founder and Vice President of Science Strategy of the spin-out Artios Pharma and Chair of CRUK’s Discovery Research Committee.

He talks about the dawn of the field of DNA damage repair, why an entrepreneurial approach to your research is so valuable and the importance of venture capital in the innovation landscape. 


Useful links

Explore the formation of Artios Pharma and the role of Cancer Research Horizons in translation

https://news.cancerresearchuk.org/2021/11/05/taking-on-dna-repair-to-tackle-cancer/


Explore RadNet. Whether you’re a cancer biologist, health professional, engineer or physical scientist, RadNet is an exciting and rewarding opportunity to apply your expertise and knowledge

https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/radnet-our-radiation-research-network


Register your interest for the CRUK-ARR Radiation Research Conference https://forms.office.com/Pages/ResponsePage.aspx?id=L4lzROBx_EaN7Cc5ArUTSeNZ7IzS7O9ItRV1smdjkd1UMDBYRUI1SzRPSThYNTZEUDhSSzZSSUJKVi4u


Find out how Cancer Research Horizons can help you translate your work

https://www.cancerresearchhorizons.com/collaborate-us/researchers


Listen to Professor Steve Jackson on a previous episode

https://shows.acast.com/cancer-research-matters/episodes/translation-tales-20-years-of-forming-spinout

Hosted on Acast. See acast.com/privacy for more information.

]]> Stigma, hope and TRACERx: 20 years of understanding lung cancer Stigma, hope and TRACERx: 20 years of understanding lung cancer Tue, 01 Nov 2022 08:33:25 GMT 30:19 635aa2e6aefe260012d684a9 false https://shows.acast.com/cancer-research-matters/episodes/stigma-hope-and-tracerx-20-years-of-understanding-lung-cance 635aa2e6aefe260012d684a9 61fbe28ea451000014525587 stigma-hope-and-tracerx-20-years-of-understanding-lung-cance full 1 7 This episode features Professor Charles Swanton. Charlie is Cancer Research UK's Chief Clinician and his lab at the Francis Crick Institute studies lung cancer tumour heterogeneity and maps the evolutionary pathways at work as cancers evolve and change.


He talks about the profound changes in the way the research community thinks about lung cancer, the power of the translational mind-set and delves into the flagship project, TRACERx.


He also talks briefly about his lab’s growing interest in the mechanistic links between air pollution and lung cancer in never smokers.


Useful links

Explore how Cancer Research Horizons can help you translate your work

https://www.cancerresearchhorizons.com/our-expertise/research-translation


Read about Charlie’s work on air pollution and lung cancer  https://news.cancerresearchuk.org/2021/12/13/its-a-fair-cop-why-our-chief-clinician-went-to-a-climate-change-summit/


ScottishPower and Cancer Research UK, working together for a greener, healthier future

Our longstanding partner ScottishPower is helping us shine a light on the role air pollution plays in cancer and are covering the cost of a study called TOPICAL. ScottishPower is 100% committed to helping tackle climate change and our partnership reflects our shared interest in a greener, healthier future.


Hosted on Acast. See acast.com/privacy for more information.

]]> This episode features Professor Charles Swanton. Charlie is Cancer Research UK's Chief Clinician and his lab at the Francis Crick Institute studies lung cancer tumour heterogeneity and maps the evolutionary pathways at work as cancers evolve and change.


He talks about the profound changes in the way the research community thinks about lung cancer, the power of the translational mind-set and delves into the flagship project, TRACERx.


He also talks briefly about his lab’s growing interest in the mechanistic links between air pollution and lung cancer in never smokers.


Useful links

Explore how Cancer Research Horizons can help you translate your work

https://www.cancerresearchhorizons.com/our-expertise/research-translation


Read about Charlie’s work on air pollution and lung cancer  https://news.cancerresearchuk.org/2021/12/13/its-a-fair-cop-why-our-chief-clinician-went-to-a-climate-change-summit/


ScottishPower and Cancer Research UK, working together for a greener, healthier future

Our longstanding partner ScottishPower is helping us shine a light on the role air pollution plays in cancer and are covering the cost of a study called TOPICAL. ScottishPower is 100% committed to helping tackle climate change and our partnership reflects our shared interest in a greener, healthier future.


Hosted on Acast. See acast.com/privacy for more information.

]]> Side effects and sub-types: 20 years of understanding childhood cancer Side effects and sub-types: 20 years of understanding childhood cancer Tue, 06 Sep 2022 10:12:07 GMT 23:23 63171cf72e926e0013f5e6fe false https://shows.acast.com/cancer-research-matters/episodes/side-effects-and-sub-types-20-years-of-understanding-childho 63171cf72e926e0013f5e6fe 61fbe28ea451000014525587 side-effects-and-sub-types-20-years-of-understanding-childho full 1 6 Cancer Research Matters, a new Podcast from Cancer Research UK featuring some of the incredible researchers behind cancer research. The idea is to drive and provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

The first series focusses on the 20th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.


This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He has dedicated his career to understanding childhood brain tumours and is perhaps known best for his work identifying different types of medulloblastoma and ependymoma – two of the most common kinds of childhood brain tumour. 

He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.  


Further reading

WNT signalling and brain cancer

https://link.springer.com/article/10.1007/s00401-012-0958-8

https://www.sciencedirect.com/science/article/pii/S1535610816300551

Read about CRUK’s data strategy

https://news.cancerresearchuk.org/2022/07/07/joining-the-dots-how-our-new-research-data-strategy-will-unlock-the-power-of-big-data/

See the data strategy

https://www.cancerresearchuk.org/sites/default/files/cancer_research_uk_-_research_data_strategy.pdf

Hosted on Acast. See acast.com/privacy for more information.

]]> Cancer Research Matters, a new Podcast from Cancer Research UK featuring some of the incredible researchers behind cancer research. The idea is to drive and provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

The first series focusses on the 20th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.


This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He has dedicated his career to understanding childhood brain tumours and is perhaps known best for his work identifying different types of medulloblastoma and ependymoma – two of the most common kinds of childhood brain tumour. 

He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.  


Further reading

WNT signalling and brain cancer

https://link.springer.com/article/10.1007/s00401-012-0958-8

https://www.sciencedirect.com/science/article/pii/S1535610816300551

Read about CRUK’s data strategy

https://news.cancerresearchuk.org/2022/07/07/joining-the-dots-how-our-new-research-data-strategy-will-unlock-the-power-of-big-data/

See the data strategy

https://www.cancerresearchuk.org/sites/default/files/cancer_research_uk_-_research_data_strategy.pdf

Hosted on Acast. See acast.com/privacy for more information.

]]> Complexity and understanding - 20 years of tumour suppression with Karen Vousden Complexity and understanding - 20 years of tumour suppression with Karen Vousden Thu, 25 Aug 2022 11:37:49 GMT 23:20 63075f0eeb49dd00143788d5 false https://shows.acast.com/cancer-research-matters/episodes/complexity-and-understanding-20-years-of-tumour-suppression- 63075f0eeb49dd00143788d5 61fbe28ea451000014525587 complexity-and-understanding-20-years-of-tumour-suppression- full 1 5 This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She has been the director of the Cancer Research UK Beatson Institute in Glasgow, UK, and from 2016 she re-located to become a group leader at the Francis Crick Institute as well as taking up the role of Chief Scientist at CRUK.


She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed.


Further reading on Karen’s work on p53:

Article Following the discovery of p53

p53 is strictly controlled in the normal cell, Karen discovered that a key element in this regulation is the protein Mdm2. https://www.jbc.org/article/S0021-9258(18)30208-4/fulltext

Karen’s work on oncogenes and HPV: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC402081/

Hosted on Acast. See acast.com/privacy for more information.

]]> This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She has been the director of the Cancer Research UK Beatson Institute in Glasgow, UK, and from 2016 she re-located to become a group leader at the Francis Crick Institute as well as taking up the role of Chief Scientist at CRUK.


She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed.


Further reading on Karen’s work on p53:

Article Following the discovery of p53

p53 is strictly controlled in the normal cell, Karen discovered that a key element in this regulation is the protein Mdm2. https://www.jbc.org/article/S0021-9258(18)30208-4/fulltext

Karen’s work on oncogenes and HPV: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC402081/

Hosted on Acast. See acast.com/privacy for more information.

]]> The creative act of science - 20 years of leadership in cancer research The creative act of science - 20 years of leadership in cancer research Tue, 19 Jul 2022 16:26:19 GMT 25:15 62cd984865d3e90015692135 false https://shows.acast.com/cancer-research-matters/episodes/the-creative-act-of-science-20-years-of-leadership-in-cancer 62cd984865d3e90015692135 61fbe28ea451000014525587 the-creative-act-of-science-20-years-of-leadership-in-cancer We celebrate 20 years of Cancer Research UK with Professor Sir Leszek Borysiewicz full 1 4 This episode features CRUK Chairman, Professor Sir Leszek Borysiewicz. Following a distinguished academic and clinical research career, Leszek’s roles have included Chief Executive of the Medical Research Council and Vice Chancellor of the University of Cambridge. He is a founding Fellow of the Academy of Medical Sciences and was awarded a Knighthood in 2001 for his pioneering work on HPV vaccines. Early teenage girls are now routinely vaccinated for HPV, with the UK having among the highest uptake worldwide.


He talks about the development of the HPV vaccine, the difficulties of navigating a research career and why we must start to embrace failure… even a negative result, he says, is positive.


Further reading on the HPV vaccine:

Journal paper:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02178-4/fulltext

Article:

https://news.cancerresearchuk.org/2021/11/03/the-power-of-science-hpv-vaccine-proven-to-dramatically-reduce-cervical-cancer/

Hosted on Acast. See acast.com/privacy for more information.

]]> This episode features CRUK Chairman, Professor Sir Leszek Borysiewicz. Following a distinguished academic and clinical research career, Leszek’s roles have included Chief Executive of the Medical Research Council and Vice Chancellor of the University of Cambridge. He is a founding Fellow of the Academy of Medical Sciences and was awarded a Knighthood in 2001 for his pioneering work on HPV vaccines. Early teenage girls are now routinely vaccinated for HPV, with the UK having among the highest uptake worldwide.


He talks about the development of the HPV vaccine, the difficulties of navigating a research career and why we must start to embrace failure… even a negative result, he says, is positive.


Further reading on the HPV vaccine:

Journal paper:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02178-4/fulltext

Article:

https://news.cancerresearchuk.org/2021/11/03/the-power-of-science-hpv-vaccine-proven-to-dramatically-reduce-cervical-cancer/

Hosted on Acast. See acast.com/privacy for more information.

]]> Microenvironments and early detection - 20 years of proteomics in cancer research Microenvironments and early detection - 20 years of proteomics in cancer research Mon, 23 May 2022 10:12:29 GMT 24:48 6287a69b24fb6200129f2ae7 false https://shows.acast.com/cancer-research-matters/episodes/microenvironments-and-early-detection-20-years-of-proteomics 6287a69b24fb6200129f2ae7 61fbe28ea451000014525587 microenvironments-and-early-detection-20-years-of-proteomics We celebrate 20 years of Cancer Research UK with Professor Sara Zanivan full 1 3 This episode features Sara Zanivan. Sara is a Professor at the Beatson Institute for Cancer where she uses a number proteomics approaches to explore the tumour microenvironment. Her lab also applies their proteomics expertise and capability to develop cancer early detection approaches. Specifically, she is interested in utilising mass-spectrometry to examine how large proteomic changes could be used in the clinic. 

          

She talks about how understanding the tumour microenvironment has developed over the past 20 years, how the techniques of proteomics have really freed researchers to ask the important questions and why we could even see mass-spec proteomics in the clinic.     


Further reading on mass-spectrometry and proteomics:

Journal paper:

https://www.nature.com/articles/nature01511

Article:

https://portlandpress.com/biochemist/article/42/5/64/226371/A-beginner-s-guide-to-mass-spectrometry-based

Hosted on Acast. See acast.com/privacy for more information.

]]> This episode features Sara Zanivan. Sara is a Professor at the Beatson Institute for Cancer where she uses a number proteomics approaches to explore the tumour microenvironment. Her lab also applies their proteomics expertise and capability to develop cancer early detection approaches. Specifically, she is interested in utilising mass-spectrometry to examine how large proteomic changes could be used in the clinic. 

          

She talks about how understanding the tumour microenvironment has developed over the past 20 years, how the techniques of proteomics have really freed researchers to ask the important questions and why we could even see mass-spec proteomics in the clinic.     


Further reading on mass-spectrometry and proteomics:

Journal paper:

https://www.nature.com/articles/nature01511

Article:

https://portlandpress.com/biochemist/article/42/5/64/226371/A-beginner-s-guide-to-mass-spectrometry-based

Hosted on Acast. See acast.com/privacy for more information.

]]> Translation tales - 20 years of forming spinouts Translation tales - 20 years of forming spinouts Wed, 23 Mar 2022 16:19:02 GMT 25:42 623b4876f292300012680a4d false https://shows.acast.com/cancer-research-matters/episodes/translation-tales-20-years-of-forming-spinout 623b4876f292300012680a4d 61fbe28ea451000014525587 translation-tales-20-years-of-forming-spinout We celebrate 20 years of Cancer Research UK with Professor Steve Jackson full 1 2 Steve Jackson is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. Steve’s main academic work is in the field of DNA damage repair, but he also founded KuDOS Pharmaceuticals in order to translate and market the PARP inhibitor Olaparib/ Lynparza. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research.


Further reading on the commercialisation of DNA repair inhibitors:

Article:

https://news.cancerresearchuk.org/2020/09/24/parp-inhibitors-halting-cancer-by-halting-dna-repair/

Paper:

https://www.nature.com/articles/nature03445


Explore how we can work with you to help translate your work



Hosted on Acast. See acast.com/privacy for more information.

]]> Steve Jackson is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. Steve’s main academic work is in the field of DNA damage repair, but he also founded KuDOS Pharmaceuticals in order to translate and market the PARP inhibitor Olaparib/ Lynparza. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research.


Further reading on the commercialisation of DNA repair inhibitors:

Article:

https://news.cancerresearchuk.org/2020/09/24/parp-inhibitors-halting-cancer-by-halting-dna-repair/

Paper:

https://www.nature.com/articles/nature03445


Explore how we can work with you to help translate your work



Hosted on Acast. See acast.com/privacy for more information.

]]> A PARPing success - 20 years of targeting DNA repair A PARPing success - 20 years of targeting DNA repair Thu, 03 Feb 2022 14:47:01 GMT 22:26 61fbea69f10d1400125ba58e false https://shows.acast.com/cancer-research-matters/episodes/a-parping-success-20-years-of-targeting-dna-repair 61fbea69f10d1400125ba58e 61fbe28ea451000014525587 a-parping-success-20-years-of-targeting-dna-repair We celebrate 20 years of Cancer Research UK with Professor Ruth Plummer full 1 1 Ruth Plummer is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.


Further reading on PARP inhibitors

The development and translation of PARP inhibitors:

https://news.cancerresearchuk.org/2020/09/24/parp-inhibitors-halting-cancer-by-halting-dna-repair/


Paper:

https://www.nature.com/articles/nature03445


General information on PARP inhibitors:

https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/targeted-cancer-drugs/types/PARP-inhibitors

Hosted on Acast. See acast.com/privacy for more information.

]]> Ruth Plummer is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.


Further reading on PARP inhibitors

The development and translation of PARP inhibitors:

https://news.cancerresearchuk.org/2020/09/24/parp-inhibitors-halting-cancer-by-halting-dna-repair/


Paper:

https://www.nature.com/articles/nature03445


General information on PARP inhibitors:

https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/targeted-cancer-drugs/types/PARP-inhibitors

Hosted on Acast. See acast.com/privacy for more information.

]]>